Dacomitinib (PF-00299804), an Irreversible Pan-Her Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-11-0730
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and Is Synergistic With Trastuzumab in Vitro and in Vivo

Clinical Cancer Research
Cancer ResearchOncology
2010English

Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It

Clinical Medicine Insights: Oncology
Oncology
2016English

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2013English

Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells With Primary Trastuzumab Resistance

Anti-Cancer Agents in Medicinal Chemistry
Cancer ResearchMolecular MedicinePharmacology
2012English

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-Negative HER2-Overexpressed Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Preliminary Safety Data of Preoperative Chemotherapy Plus Trastuzumab, Lapatinib or Both in HER2-positive Operable Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2007English

Preclinical Antitumor Activity of BMS-599626, a Pan-Her Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling

Clinical Cancer Research
Cancer ResearchOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy